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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

LAW ENFORCEMENT AND EXECUTIVE ORDER: DUPLICATION
IN MISSOURI’S PRESCRIPTION DRUG MONITORING PROGRAM

ABSTRACT
Missouri had long been scrutinized as the only state operating without a
prescription drug monitoring program. These programs are seen as an effective
way to monitor prescription opioids as opioid-related deaths have risen in the
past decade. The opioid crisis has gained significant media attention and cast
scrutiny on pharmaceutical companies, physicians, and state and federal
governments. This comment explores the history of the opioid crisis and details
Missouri’s struggle to implement a prescription drug monitoring program
legislatively. In 2017, former Governor Eric Greitens signed an Executive Order
directing the Missouri Department of Health and Senior Services to implement
one of these programs. This program is centered on law enforcement, and as
written, aims to monitor and collect data that is already available via alternative
means. For Missouri to successfully combat the opioid crisis, the state needs to
utilize resources already at its disposal to create an effective means of
monitoring prescription opioids. At the time of publication, the program had
been implemented; however, there is no available data currently available to
determine the effectiveness of the program.
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I. INTRODUCTION
Beginning in 1999, the use of opioids, both legal and illegal, has risen
drastically; opioid-related deaths have increased significantly over the past
decade. 1 This crisis has quickly become one of the most discussed issues in the
United States. Media coverage has increased with state and federal legislatures
shining light on the issue as they struggle to find a solution. In October of 2016,
President Trump declared the opioid crisis a “public health emergency.” 2 At the
time of his announcement, he had not requested any funds to combat the issue
but plans on “really tough, really big, really great advertising” as a means to help
minimize the number of those addicted to opioids in the nation. 3 The President
revisited this issue in his first State of the Union Address in January of 2018, 4
and in March, the White House established a new website “where Americans
can share their own stories about the dangers of opioid addiction.” 5 Many states
have undertaken differing and even multiple approaches to combat the number
of opioid-related deaths they see in their state. 6
Missouri, like the nation, has not been immune to the effects of opioids.7
While opioids, when prescribed and used appropriately, can be effective at
managing pain, the misuse of these drugs can lead to addiction and death.
Missouri’s high use of opioids, especially in rural areas, is attributed to fewer
options for pain management like physical therapy, older populations that are
prescribed opioids for cancer or end-of-life treatment, and urban areas that have
greater access to illegal drugs like heroin. 8 While Missouri has been aware of
this growing problem, the legislature has been unsuccessful in passing
legislation to create a statewide prescription drug monitoring program (PDMP). 9
In July of 2017, Missouri Governor Eric Greitens attempted to tackle the use
of opioids in Missouri by signing an executive order, directing the Department
1. Understanding the Epidemic, CTRS. FOR DISEASE CONTROL & PREVENTION (Aug. 30,
2017), https://www.cdc.gov/drugoverdose/epidemic/index.html.
2. Julie Hirschfeld Davis, Trump Declares Opioid Crisis a ‘Health Emergency’ But Requests
No Funds, N.Y. TIMES (Oct. 26, 2017), https://www.nytimes.com/2017/10/26/us/politics/trumpopioid-crisis.html.
3. Id.
4. President Donald J. Trump, State of the Union Address (Jan. 30, 2018).
5. The Opioid Crisis, WHITE HOUSE, https://www.whitehouse.gov/opioids/ (last visited Oct.
13, 2018).
6. See Gale Pryor, 6 Ways States are Fighting the Opioid Epidemic, ATHENA INSIGHT (May
19, 2017), https://www.athenahealth.com/insight/6-ways-states-are-fighting-opioid-epidemic.
7. Andy Marso, These are the Most Opioid-Soaked Counties in Kansas and Missouri, KAN.
CITY STAR (July 30, 2017), http://www.kansascity.com/news/business/health-care/article1643078
57.html.
8. Id.
9. Rick Morgan, Running Out of Time: Missouri’s Opioid Epidemic, VOX MAG. (Apr. 6,
2017),
http://www.voxmagazine.com/news/features/running-out-of-time-missouri-s-opioid-epi
demic/article1b2d4f10-1ad2-11e7-a4e0-7f7f4ba7c6e6.html.
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of Health and Senior Services (DHSS) to implement a statewide PDMP using a
three-step process. 10 The program went into effect at the end of the 2017
calendar year, with data already being shared between prescribers and the state
via a pharmacy benefit management firm. 11 The program he proposed is not
designed to operate as a traditional PDMP, but rather as a surveillance program.
The data that Governor Greitens’s order collects is already available through
other means in the state of Missouri. The state currently utilizes a statewide
health information exchange (HIE) that shares electronic medical records
(EMRs) with participants across the state, as well as smaller HIEs that operate
regionally. In Missouri, the Bureau of Narcotics and Dangerous Drugs (BNDD)
must maintain a registry of practitioners who deal with controlled substances,
including Schedule II opioids, and there are currently reporting requirements for
practitioners and pharmacists for controlled substances that are dispensed.
The Executive Order to implement a PDMP aims to combat the opioid crisis
by punishing prescribers. However, the data that is collected and turned over to
law enforcement is already available to law enforcement via multiple means,
making Missouri’s PDMP an additional and duplicative step in monitoring
prescription opioids. This comment will explore how and why there was a rise
in the number of prescription opioids across the nation, discuss PDMPs as a way
to monitor opioids, navigate Missouri’s struggle with opioid-related deaths and
lack of legislation to combat those deaths, and examine why Missouri’s PDMP
is a law enforcement-centered program that is duplicative of other systems that
are already in place to monitor the amount of prescribed and dispensed opioids
in the state. Finally, this comment will conclude with an evaluation of Nebraska
and how the state has dealt with the increase in opioids as a best practice and
potential model for Missouri, which the state should adopt as an alternative
practice in monitoring opioids dispensed throughout the state.
II. OPIOID CRISIS
To first understand the impacts that opioids have had across the country, one
must look to the history of opioids in the United States; prescribing practices
have changed over time prior to landing in the current landscape where the
amount of opioid use (and deaths) are called both a “crisis” and “epidemic.” 12

10. Mo. Exec. Order No. 17-18 (July 17, 2017).
11. Jack Suntrup & Samantha Liss, Missouri’s Version of Long-Awaited Prescription
Monitoring Program is Up and Running, ST. LOUIS POST DISPATCH (Dec. 9, 2017), http://www.stl
today.com/news/local/govt-and-politics/missouri-s-version-of-long-awaited-prescription-monitor
ing-program-is/article_082eaa5c-a898-5510-9158-557a2bef144c.html.
12. See generally Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE (Mar. 2018),
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis; Opioid Crisis Fast Facts,
CNN (May 27, 2018), https://www.cnn.com/2017/09/18/health/opioid-crisis-fast-facts/index.html;
What is the U.S. Opioid Epidemic?, DEP’T OF HEALTH & HUMAN SERVS. (Mar. 6, 2018),
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Opioid use in the United States did not begin over the past three decades; opioids
were used recreationally and for pain management in the United States for
centuries. When morphine was extracted from opium in 1803, it was used to
treat pain in the Civil War. 13 After seeing the addictive effects of opioids,
scientists worked to develop a less addictive solution that maintained the
effectiveness in relieving pain of opioids. This led to the development of heroin,
which was more addictive than the morphine that was previously used. 14
Medical professionals, seeing the addictive effects of both morphine and heroin,
were concerned with opioid use, which resulted in a decline in medical opioids
through the twentieth century. 15 Research continued to search for alternatives,
leading to the introduction of Vicodin and Percocet, which were made using
synthetic opioids. 16
The most credited reason for the increase in prescribing opioids in past
decades relates back to the state of medicine during the 1990s. During this time,
physicians were told that they were not adequately treating patients’ pain. 17
Patients were surveyed as they left hospitals after receiving treatment, and while
their ailment or reason for visit may have been treated, their pain was not. 18 In
addition, there is evidence that untreated pain hampers healing and recovery
from opiod addiction, which can lead to self-medication and the purchase of
illegal opioids. 19 There then came a greater push for physicians not only to treat
ailments, diseases, and the like, but also to treat patients’ pain. 20 Pain was
introduced as the “fifth vital sign” to be assessed during treatment, and pain was
treated as a public health issue. 21 In response, pharmaceutical companies began
to more aggressively market opioids, such as OxyContin. 22 Physicians faced
https://www.hhs.gov/opioids/about-the-epidemic/; America’s Opioid Epidemic, CBS NEWS,
https://www.cbsnews.com/opioid-epidemic/ (last visited Oct. 13, 2018).
13. NAT’L ACADS. OF SCIS., ENG’G, & MED., PAIN MANAGEMENT AND THE OPIOID
EPIDEMIC: BALANCING SOCIETAL AND INDIVIDUAL BENEFITS AND RISKS OF PRESCRIPTION
OPIOID USE 1–6, 24 (2017).
14. Id.
15. Id. at 1–7.
16. Id.
17. See generally Rachel Solnick, Prescription Drug Monitoring Programs: Regulatory
Burden or an Emergency Physician Function?, ACEP NOW (July 15, 2016), http://www.acepnow.
com/article/prescription-drug-monitoring-programs-regulatory-burden-emergency-physician-func
tion/?singlepage=1&theme=print-friendly.
18. See generally id.
19. Amy Wachholtz et al., Intersection of Chronic Pain Treatment & Opioid Analgesic
Misuse: Causes, Treatments, & Policy Strategies, SUBSTANCE ABUSE & REHABILITATION, Aug.
17, 2011, at 146, 157.
20. Solnick, supra note 17.
21. Id.; Daniel S. Goldberg & Summer J. McGee, Pain as a Global Public Health Priority,
BMC PUB. HEALTH, Oct. 6, 2011, at 3.
22. Solnick, supra note 17; Wachholtz et al., supra note 19, at 146; see also NAT’L ACADS.
OF SCIS., ENG’G, MED., supra note 13 at 1–8.
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backlash when they were told they were not adequately treating pain; physicians
are now facing backlash for prescribing too many opioids in the attempt to treat
pain. Now, physicians face finger pointing and blame from families affected by
opioids, legislatures, and even the media, not to mention punishment from law
enforcement and licensing boards. 23
The increase in the amount of prescription opioids, such as oxycodone,
hydrocodone, and methadone, has risen since 1999, and opioid-related deaths
are associated with that increase since that time. 24 The Centers for Disease
Control and Prevention (CDC) report data on four categories of opioids: natural,
synthetic, methadone, and heroin. 25 The CDC estimates that 115 Americans die
from an opioid overdose every day. 26 While the CDC is reporting increases in
prescription opioids and deaths related to overdoses, they admit that the data
they report may not be complete. 27 This may be attributed not only to an increase
in prescription drugs, but also an increase in the illegal use of heroin and
fentanyl. 28 The CDC is not the only agency reporting an increase in opioidrelated deaths; law enforcement is also reporting greater numbers of synthetic
opioids on the market. 29 Even in the early 2000s when authorities were seeing
tampering and illegal selling of prescriptions, pharmaceutical sales of opioids
continued to increase. 30 In addition to the increase in deaths, “adverse health
consequences resulting from prescription drug misuse—including overdose
events, emergency department (“ED”) visits, and inpatient admissions—have
escalated dramatically.” 31 The rise in opioid-related deaths has increased more
quickly in the United States than in other countries. 32
While there has been an increase in opioid overdoses, the majority of
patients “prescribed opioids do not misuse them.” 33 A common use of opioids is
23. Solnick, supra note 17; Marcia Frellick, Physicians Get Too Much Blame for Opioid
Crisis, Some Say, MEDSCAPE (June 24, 2018), https://www.medscape.com/viewarticle/885760#
vp_3; see also, Sarah Schulte, Wheaton Family Sues Hospital Over Grandmother’s Opioid
Overdoes Death, ABC7CHICAGO (May 11, 2018), http://abc7chicago.com/health/wheaton-familysues-hospital-over-grandmothers-opioid-overdose-death/3461909/.
24. Understanding the Epidemic, supra note 1.
25. Opioid Data Analysis, CTRS. FOR DISEASE CONTROL & PREVENTION (Feb. 9, 2017),
https://www.cdc.gov/drugoverdose/data/analysis.html.
26. Understanding the Epidemic, supra note 1.
27. Pat Anson, CDC Admits Rx Opioid Deaths ‘Significantly Inflated’, PAIN NEWS NETWORK
(Mar. 21, 2018), https://www.painnewsnetwork.org/stories/2018/3/21/cdc-admits-rx-opioiddeaths-significantly-inflated.
28. Opioid Data Analysis, supra note 25.
29. Id.
30. NAT’L ACADS. OF SCIS., ENG’G, AND MED., supra note 13, at 1–8.
31. Rebecca L. Haffajee, Preventing Opioid Misuse with Prescription Drug Monitoring
Programs: A Framework for Evaluating the Success of State Public Health Laws, 67 HASTINGS
L.J. 1621, 1630 (2016).
32. NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 13, at ix.
33. Id. at S-2.
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to manage chronic pain in patients suffering from cancer and end-of-life
treatment. Those who are being treated for acute pain with opioids, however,
may experience the positive and euphoric feelings of the drugs, leading to the
addiction that patients may face. 34 The physicians prescribing opioids are not
the only cause to the increase of opioids; “while increased opioid prescribing for
chronic pain has been a vector of the opioid epidemic, researchers agree that
such structural factors as lack of economic opportunity, poor working
conditions, and eroded social capital in depressed communities, accompanied by
hopelessness and despair, are root causes of the misuse of opioids . . . .” 35
Physicians should not have to shoulder all the blame for this issue; there are
many factors that have led to the increase of opioids, and the focus should be on
how to prevent opioid abuse and overdose.
A.

State Strategies to Address Opioid Misuse

States have not sat idly by waiting for the opioid crisis to solve itself;
numerous strategies have been presented to states as suggestions on how to limit
opioid-related deaths. The Commission on Combatting Drug Addiction and
Opioid Crisis released a draft of a report that outlines suggestions for states to
follow in working to limit the number of opioid-related deaths. 36 Some of the
suggestions for prescribers include Medication Assistance Treatment
programs 37 and PDMPs with interstate sharing systems allowing prescribers to
have access to patient prescription data. 38 Other suggested approaches include:
setting prescribing limits and guidelines for physicians, which would limit the
dose and amounts of opioids; expanding access to treatment to those suffering
addiction, including providing sufficient insurance coverage for inpatient
treatment facilities; working to minimize the long wait for those seeking
treatment in those facilities; and expanding access to the drug Naloxone, which
“blocks the effects of opioids to reverse overdoses within minutes.” 39
Continuing Medical Education for prescribers is a commonly recommended
strategy that relates directly to the amount of prescription opioids on the market.
Fully implementing this strategy will necessitate “a fundamental shift in the

34. Id. at 3–29.
35. Id. at 1–19.
36. COMM’N ON COMBATING DRUG ADDICTION & THE OPIOID CRISIS, INTERIM REPORT 2
(2017),
https://www.whitehouse.gov/sites/whitehouse.gov/files/ondcp/commission-interim-re
port.pdf.
37. See Medication-Assisted Treatment, SUBSTANCE ABUSE & MENTAL HEALTH SERVS.
ADMIN. (last updated Feb. 7, 2018), https://www.samhsa.gov/medication-assisted-treatment
(explaining this approach implements “the use of FDA-approved medications, in combination with
counseling and behavioral therapies, to provide a ‘whole-patient’ approach to the treatment of
substance use disorders.”).
38. COMM’N ON COMBATING DRUG ADDICTION & THE OPIOID CRISIS, supra note 36, at 7.
39. Pryor, supra note 6.
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nation’s approach to mandating pain-related education for all health
professionals who provide care to individuals with pain. Prescribing guidelines
may be able to improve provider prescribing behavior, but may be most effective
when accompanied by education and other measures to facilitate
implementation.” 40 The Food and Drug Administration (FDA) recommends
employing mitigation strategies in an attempt to be proactive in combatting
opioid use as well as creating a greater push for abuse-deterrent opioids, for
example, pills that are more difficult to crush and be used recreationally. 41
Thirteen states have implemented limits on prescription opioid amounts in
order to limit opioid use. 42 Working to prevent opioid addiction from the start is
another way to limit the number of prescribed opioids, as well as identifying and
treating early cases of addiction and effectively treating those who are currently
addicted. 43 Some states require a physical examination prior to prescribing
opioids, or at least an evaluation of the patient “that is deemed ‘appropriate’…
instead of or in addition to the physical examination laws.” 44 Opioid misuse
strategies can be categorized into three stages: primary, secondary, and tertiary
prevention. 45 These intervention strategies address opioid use from initiation to
prescription (i.e. prescriber education, manufacturer regulation), to screening for
addiction (including urine testing and PDMPs), and finally to addressing
addiction through rehabilitation. 46
B.

PDMPs

Of the many suggestions and strategies, all states (including Missouri as of
2017) have chosen to implement PDMPs. 47 PDMPs can be used not only to limit
the number and dosage of opioids a patient receives, but they also help a
prescriber or pharmacist identify any potential conflicts a patient may have with

40. NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 13, at S-10.
41. Dani Kass, 3 Takeaways from the FDA Head’s New Opioid Rx Standards, LEXIS LAW360
1–2 (July 12, 2017), https://advance.lexis.com/document/?pdmfid=1000516&crid=8901a68c-b0
9a-4612-b403-1c07b1d5a28a&pddocfullpath=%2Fshared%2Fdocument%2Flegalnews%2Furn%
3AcontentItem%3A5P0S-N6B1-F22N-X290-00000-00&pddocid=urn%3AcontentItem%3A5P0
S-N6B1-F22N-X290-00000-00&pdcontentcomponentid=122080&pdteaserkey=sr0&ecomp=kyf
fk&earg=sr0&prid=0997b46d-12ac-4d45-bb68-45eb2aef646e.
42. Pryor, supra note 6.
43. Haffajee, supra note 31, at 1631–32.
44. Prescription Drug Physical Examination Requirements, CTRS. FOR DISEASE CONTROL &
PREVENTION 1, 3 (Jan. 29, 2015), https://www.cdc.gov/phlp/docs/pdpe-requirements.pdf.
45. Haffajee, supra note 31, at 1633–34.
46. Id.
47. See id. at 1635; see also Jason Hancock & Andy Marso, Gov. Eric Greitens Orders
Prescription Drug Monitoring Program for Missouri, KAN. CITY STAR (July 17, 2017),
http://www.kansascity.com/news/local/news-columns-blogs/the-buzz/article161759233.html.
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existing medications. 48 PDMPs are an achievable means of allowing prescribers
to track prescription information for a patient, even though state laws differ in
what information can be viewed and tracked. 49 Goals of a PDMP include:
improving patient treatment decisions; influencing prescribing practices;
assisting in the identification of “doctor shoppers;” and serving as a tool for law
enforcement. 50 When a physician utilizes a PDMP, she can see if the patient has
on-going opioid prescriptions, if the patient is receiving the same prescription
from multiple doctors, 51 and even the dose, supply, and prescriber of other
prescriptions, 52 allowing the physician to determine if the patient is an addict or
abuser of prescription opioids. Studies suggest the mandatory use of PDMPs is
best practice; unsurprisingly, PDMPs have been shown to be most effective in
states that mandate their use. 53 When use is not mandated, little more than half
of physicians regularly utilize their state’s PDMP, 54 undercutting the value a
PDMP could have to prescribers and their state’s efforts to more closely monitor
and limit the number of prescription opioids dispensed. To more effectively
utilize PDMPs:
The U.S. Department of Health and Human Services, in concert with state
organizations that administer prescription drug monitoring programs, should
conduct or sponsor research on how data from these programs can best be
leveraged for patient safety (e.g., data on drug–drug interactions), for
surveillance of policy and other interventions focused on controlled substances
(e.g., data on trends in opioid prescribing, effects of prescriber guidelines), for
health service planning (e.g., data on discrepancies in dispensing of medications
for treatment of opioid use disorder), and for use in clinical care (i.e., in clinical
decision making and patient–provider communication). 55

The data found in a PDMP can have beneficial effects beyond merely tracking
prescription history.
There are generally two goals when implementing a PDMP: public health
and law enforcement. PDMPs that utilize public health as their primary goal
48. Austin Frakt, A Helpful Tool to Combat the Opioid Crisis, N.Y.TIMES (Sept. 11, 2017),
https://www.nytimes.com/2017/09/11/upshot/a-helpful-tool-to-combat-the-opioid-crisis.html.
49. NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 13, at S-10.
50. Lainie Rutkow et al., Prescription Drug Monitoring Program Design and Function: A
Qualitative Analysis, 180 DRUG & ALCOHOL DEPENDENCE 395, 397 (2017) (explainging while a
PDMP can be used as a tool for law enforcement, “providing data to health care providers was, in
general, the primary purpose of the PDMP.”).
51. Frakt, supra note 48.
52. Haffajee, supra note 31, at 1634.
53. See, e.g., Frakt, supra note 48; Janet Weiner et al., Prescription Drug Monitoring
Programs: Evolution & Evidence, LEONARD DAVIS INST. OF HEALTH ECON. 1, 6 (2017),
https://ldi.upenn.edu/sites/default/files/pdf/LDI%20CHERISH%20Brief_Prescription%20Drug%
20Monitoring%20Programs.pdf.
54. Weiner et al., supra note 53, at 1.
55. NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 13, at S-11.
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have a greater focus on lowering the amount of opioid-related deaths and access
to treatment and education to those suffering opioid addiction. 56 Public health
should not be only on the minds of those initiating a PDMP; the FDA should
also incorporate public health issues when making “regulatory decisions
regarding opioids.” 57 In the CDC’s suggested strategies for states to fight the
abuse of opioids, the strategies suggested focus on evaluating programs that are
currently in place, not punishing prescribers or patients with the involvement of
law enforcement. 58 Because the amount of opioid use is considered a public
health concern, PDMPs should keep public health goals at the forefront of their
implementation to address a more holistic approach to confronting opioid abuse.
PDMPs with law enforcement as their primary goal focus on the prescription
abuse side of the opioid crisis. 59 They do this by working to punish the
prescribers and dispensers of opioids as well as the patients who abuse them. 60
This focus on law enforcement creates tension among the medical community,
leaving physicians feeling like there is someone “looking over their
shoulders.” 61 Physicians, working in fields that prescribe a higher than average
amount of opioids, such as end-of-life and cancer, see law enforcement’s hand
in their practice as a “nuisance.” 62 Law enforcement PDMPs look for instances
of overprescribing, or deviating from the standard of care, but this term does not
fully recognize all situations in which a patient may misuse a prescription;
opioid-seeking patients may be turning around and illegally selling their
medication. 63 In a state that does not mandate the use of the PDMP, physicians
may choose not to utilize this tool for fear of retribution by law enforcement.
Fear of punishment may deter some physicians, which may mean less
prescription opioids, but this refusal may encourage patients to obtain opioids
illegally. Patients who have legitimate need for opioids but are denied by
physicians who fear law enforcement may turn to other illegal means of pain

56. M. Mofizul Islam & Ian S. McRae, Commentary, An Inevitable Wave of Prescription Drug
Monitoring Programs in the Context of Prescription Opioids: Pros, Cons & Tensions, BMC
PHARMACOLOGY & TOXICOLOGY 1 (2014).
57. NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 13, at 6–26.
58. Promising State Strategies, CTRS. FOR DISEASE CONTROL & PREVENTION
(Aug. 30, 2017), https://www.cdc.gov/drugoverdose/policy/index.html; Islam & McRae, supra
note 56, at 3.
59. Islam & McRae, supra note 56, at 3.
60. Id. at 5.
61. Carol M. Ostrom, New Prescription Monitoring Draws Complaints, SEATTLE TIMES (Jan.
3, 2012),
http://www.seattletimes.com/seattle-news/new-prescription-monitoring-draws-com
plaints/.
62. Islam & McRae, supra note 56, at 3.
63. Kelly K. Dineen & James M. DuBois, Between a Rock and a Hard Place: Can Physicians
Prescribe Opioids to Treat Pain Adequately While Avoiding Legal Sanction?, 42 AM. J. L. & MED.
7, 13 (2016).
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management. 64 The majority of people who are abusing opioids are getting them
illegally. 65
While most PDMPs allow the authorities to gain access to information
stored on a PDMP, 66 state law varies in the scope of the obtainable evidence, 67
and even though law enforcement can obtain evidence from a PDMP, this does
not mean that the goal of the PDMP is law enforcement. The two most common
means by which an authorized recipient may receive data from PDMP are: (1)
“probable cause, search warrant, subpoena, or other judicial process;” and (2)
“pursuant to an active investigation or as part of official duties.” 68 State medical
licensing boards still have the right to punish physicians whose prescribing
practices fall below the standard of care, without any interference or
investigation conducted by law enforcement. 69 This should be an efficient check
on prescribing practices without the involvement of law enforcement.
With these dual goals, “states must balance the various means used to
achieve these various purposes against the patients’ expectations of privacy” as
well as “help states regulate controlled substances and prevent abuse of these
substances by providing prescribers, dispensers, and law enforcement with the
information necessary to identify individuals that may be diverting prescription
drugs from legitimate channels to sell or use illicitly.” 70 One of the criticisms of
PDMPs is the fear that the information shared on these systems will constitute a
breach of privacy for the patient by allowing a physician to gain access to that
patient’s prescribing history, even when treating the patient only once. However,
PDMPs that focus on law enforcement justify their use by balancing the need
for patient privacy with the need for law enforcement to regulate opioid use. 71
Different states have different requirements for law enforcement to gain access
to the data. For example, Oregon requires “a search warrant or showing of
probable cause,” while Pennsylvania requires “approval from the attorney
general” for access. 72 Additionally, “Maine, Nebraska, and Vermont are the only
states currently that do not have a specific provision in their prescription
monitoring program laws for access by law enforcement or judicial authorities.

64. Ostrom, supra note 61.
65. Howard L. Fields, The Doctor’s Dilemma: Opiate Analgesics and Chronic Pain, 69
NEURON 591, 592 (2011).
66. Devon T. Unger, Minding Your Meds: Balancing the Needs for Patient Privacy and Law
Enforcement in Prescription Drug Monitoring Programs, 117 W. VA. L. REV. 345, 350 (2014).
67. Id.
68. NAT’L ALLIANCE FOR MODEL STATE DRUG LAWS, TYPES OF AUTHORIZED
RECIPIENTS—LAW ENFORCEMENT OFFICIALS (May 2016), http://www.namsdl.org/library/8EA2
38BF-9229-6EEE-AE16ADE1680E4153/.
69. Dineen & DuBois, supra note 63, at 24.
70. Unger, supra note 66, at 368.
71. Id.
72. Id.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2018]

LAW ENFORCEMENT AND EXECUTIVE ORDER

249

However, Nebraska is the only state that specifically prohibits access by law
enforcement.” 73
PDMPs that allow law enforcement to seek medical information in order to
punish physicians and abusers must then be tasked with making medical
decisions, including: “(1) the point at which a medical purpose becomes
illegitimate; (2) the boundaries of usual practice; and (3) the extent to which
crossing those boundaries warrants criminal liability.” 74 Properly trained law
enforcement would still lack the capabilities to make medical determinations
during the course of treatment for a patient. This would mean that law
enforcement would have the ability to say a patient does not need a certain
number of pills or a certain dosage to treat the many ailments for which opioids
are prescribed. When functioning in this way, the PDMP is essentially a tool that
law enforcement uses to punish, not one that is used to address the underlying
issues of addiction. 75
C. Missouri’s Struggle with Opioids
Missouri has not been immune to the opioid crisis, seeing the number of
deaths rise due to opioid abuse and overdose. In 2016, over 900 Missourians
died from overdosing on opioids. 76 According to the Missouri DHSS, of those
deaths, approximately 500 were from non-heroin opioids, while the remaining
were attributed to heroin. 77 Rural areas in Missouri are some of the hardest hit,
with Howell County ranked thirtieth in opioid usage nationally. 78 The addictive
effects of opioids have been widely reported, with opioids generating feelings
of euphoria and painlessness. 79 The chance of addiction of prescription opioids
is common; “about 35 percent of people prescribed a month’s supply of
painkillers become hooked for at least a year.” 80 Patients who are properly
prescribed opioids may become addicted, but when patients are cut off from
legal, prescription opioids, many turn to illegal opioids like heroin and black
market fentanyl to continue to experience the euphoric effects of opioids and
prevent withdrawals. 81

73. NAT’L ALLIANCE FOR MODEL STATE DRUG LAWS, TYPES OF AUTHORIZED
RECIPIENTS—LAW ENFORCEMENT OFFICIALS AND JUDICIAL OFFICIALS 3 (May
2016), http://www.namsdl.org/library/8E9A91A2-CD0B-7E3A-3E24D8CBAC438A16/.
74. Dineen & DuBois, supra note 63, at 31.
75. Islam & McRae, supra note 56.
76. Mo. Exec. Order No. 17-18 (July 17, 2017).
77. See MO. DEP’T OF HEALTH & HUMAN SERVS., MISSOURI RESIDENT OVERDOSE DEATHS
(2016), http://health.mo.gov/data/opioids/pdf/opioid-dashboard-slide-9.pdf.
78. Marso, supra note 7.
79. NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 13, at 2–6.
80. Morgan, supra note 9.
81. Id.
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For years, Missouri had no clear direction on how to handle the increasing
number of patients who abuse their legal opioid prescription or those abusing
illegal opiates. Missouri Attorney General Josh Hawley attempted action by
suing pharmaceutical companies claiming their “fraud and deception” led to the
opioid crisis in Missouri, and Hawley is seeking damages and civil penalties for
the alleged misrepresentation of the addictive effects of opioids. 82 Missouri joins
other states in these actions, with Mississippi being the first state to bring suit in
2015. 83 While suing pharmaceutical companies for their role in the boom in
prescription opioids may address the larger social issue of why opioid use
became so popular, Missouri remained the only state without a PDMP for years.
State legislature struggled to pass legislation implementing and funding a PDMP
for years. 84 In 2012, legislation to create a PDMP reached the Senate floor but
was filibustered by Senator Schaaf, a physician, citing patient privacy
concerns. 85 Senator Schaaf and a small number of other senators have effectively
prevented a PDMP bill from reaching the senate floor. 86 Schaaf has admitted
willingness to implement a PDMP legislatively but has conditioned his support;
the bill would need to require physician participation and hold them liable for
overdoses if the system is not appropriately used. 87 Senator Rehder, author of
the bill, agreed to consider his amendments. 88
When it appeared that Missouri could not successfully pass legislation to
implement one of the most common suggestions for combatting the opioid crisis
(and one which every other state implemented in some way), St. Louis County
in Missouri took action. In the spring of 2017, St. Louis County instituted a
PDMP that would operate first in the county but would eventually be opened to
counties across the state. 89 The St. Louis County PDMP monitors the dispensing
of Schedule II-IV controlled substances and requires pharmacies to report the
prescriptions within those categories. 90 The PDMP also requires pharmacies to

82. Missouri Attorney General Sues 3 Drug Companies Over State’s Opioid Crisis, CBS
NEWS (June 21, 2017), https://www.cbsnews.com/news/opioid-crisis-missouri-attorney-generaljosh-hawley-sues-pharmaceutical-companies/.
83. Id.
84. Morgan, supra note 9.
85. Megan Thielking, Missouri is the Only State Not Monitoring Prescription Drug Use. Will
It Finally Create a Database?, STAT NEWS (Mar. 7, 2017), https://www.statnews.com/2017/03/
07/missouri-prescription-drug-database/.
86. Id.
87. Allison Pecorin, Missouri Senator Says He’ll No Longer Block Prescription Drug
Monitoring Program, KAN. CITY STAR (Apr. 4, 2017), http://www.kansascity.com/news/politicsgovernment/article142718669.html.
88. Id.
89. St. Louis County Prescription Drug Monitoring Program, ST. LOUIS COUNTY, MO.,
http://www.stlouisco.com/HealthandWellness/PDMP (last visited June 17, 2018).
90. Id.
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report controlled prescriptions to their county public health department. 91 While
this began as a county program (as opposed to a statewide PDMP), St. Louis
County offered any county in Missouri to join their efforts and become a part of
this program; since its initial implementation, other counties, which account for
fifty-eight percent of Missouri’s population, have joined. 92 The St. Louis County
PDMP was up and running in April of 2017. The goals of this program are based
in public health:
(1) Improve controlled substance prescribing by providing critical information
regarding a patient’s controlled substance prescription history, (2) inform
clinical practice by identifying patients at high-risk who would benefit from
early interventions, and (3) reduce the number of people who misuse, abuse, or
overdose while making sure patients have access to safe, effective treatment. 93

III. LAW ENFORCEMENT AND EXECUTIVE ORDER
Continued media coverage, criticism of Missouri for being the only state
operating without a statewide PDMP, the failed attempts to once again to pass
legislation to implement such a program, and the scrutiny of Missouri’s lack of
action led Governor Greitens to address the continued rise of opioid-related
deaths. On July 17, 2017, Governor Eric Greitens announced Executive Order
17-18, which directed the Missouri DHSS to develop and implement a PDMP. 94
This order laid out three phases for this process. The first phase was to enter into
a contract with pharmacy benefit management organizations to analyze the
dispensing data. 95 Phase Two requires dispensers statewide to submit the data to
DHSS, which will then determine if there is a need for investigation. If so, they
will work with law enforcement and licensing boards. 96 The final phase is to
work with private companies and government entities to purchase technology to
monitor data. 97 After Greitens announced the PDMP in July, Greitens’s goal was
to get the program implemented and running before the opioid crisis in Missouri
worsened. 98

91. ST. LOUIS COUNTY, PRESCRIPTION DRUG MONITORING PROGRAM (2017).
92. St. Louis County Prescription Drug Monitoring Program, supra note 89; St. Louis County
Prescription Drug Monitoring Progam, ST. LOUIS COUNTY, MO., https://www.stlouisco.com/
Portals/8/docs/document%20library/PDMP/UPDATE-%20St.%20Louis%20County%20P
DMP.pdf (last visited Oct. 13, 2018).
93. St. Louis County Prescription Drug Monitoring Program, supra note 89.
94. Mo. Exec. Order No. 17-18 (July 17, 2017).
95. Id.
96. Id.
97. Id.
98. Jack Suntrup, Greitens May Have to Work with Lawmakers on Drug Monitoring Effort
After All, ST. LOUIS POST DISPATCH (Nov. 7, 2017), http://www.stltoday.com/news/local/govtand-politics/greitens-may-have-to-work-with-lawmakers-on-drug-monitoring/article_52940dfa9ca1-5acd-b6bd-159b7468091b.html.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

252

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

[Vol. 12:239

While proponents of a statewide PDMP praised the Governor for taking
action to help end opioid-related deaths in Missouri, those with more cynicism
criticized Greitens as merely attempting to appease constituents and his donors.
The announcement of the Executive Order was made at Express Scripts’ office
in St. Louis, indicating that Express Scripts was expected to receive the bid to
begin Phase One and help implement the monitoring program, which they later
did. 99 Another criticism on the proposal was that it “focuse[d] on the prescribers
and distributors of medications, such as doctors and pharmacists, who are
already regulated by the state.” 100 While the Missouri House Minority Leader
Gail Beatty called the original announcement a “publicity stunt,” the status of
the PDMP for Missouri was stalled for months before becoming operational in
November 2017. 101
Another cause for concern among critics was the order’s break from
traditional PDMPs. According to the Executive Order, prescribers do not have
access to a patient’s prescription information, which prevents them from making
medical decisions in the moment based on a patient’s past prescription
history. 102 Without that information, a physician who writes a prescription for
someone who may have another active opioid prescription may be punished
simply because they were unable to access that information using a PDMP. The
initial belief was that the program proposed by Governor Greitens would
actually be weaker than the PDMP St. Louis County put in place months
earlier. 103
The language from the Executive Order makes it clear that the goal of
Missouri’s PDMP is law enforcement as opposed to public health. Physicians
and prescribers do not have access to the prescription history of a particular
patient under this order, 104 and there is no mention in the Executive Order about
helping those addicted to opioids. 105 While there has long been a national
microscope on physicians’ prescribing practice of opioids, the Executive Order
in Missouri seems to up the ante. Fear of criminal prosecution may lead
physicians to avoid prescribing opioids at all, even in cases of legitimate need. 106
The Executive Order directs the data to be sent to DHSS or a designee to analyze
99. Id.; Suntrup & Liss, supra note 11.
100. Jason Hancock & Andy Marso, Gov. Eric Greitens Orders Prescription Drug Monitoring
Program for Missouri, KAN. CITY STAR (July 17, 2017), http://www.kansascity.com/news/local/
news-columns-blogs/the-buzz/article161759233.html.
101. Alisha Shurr, DHSS Confirms Statewide PDMP is up and Running, MO. TIMES (Jan. 10,
2018),
https://themissouritimes.com/47212/dhss-confirms-statewide-pdmp-is-up-and-running/;
Kurt Erickson & Blythe Bernhard, Painkiller Debate Isn’t Over, State Lawmakers Say, ST. LOUIS
POST DISPATCH (July 19, 2017), https://issuu.com/dmsgroup/docs/07-19-2017.pdf.
102. Mo. Exec. Order No. 17-18 (July 17, 2017); Hancock & Marso, supra note 100.
103. Hancock & Marso, supra note 100.
104. Id.
105. Mo. Exec. Order No. 17-18 (July 17, 2017).
106. Dineen & DuBois, supra note 63, at 38.
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and determine if there is an issue in prescribing history; in order to determine if
there was actually a violation, the order calls for an investigation. 107 However,
if the data is going to DHSS and law enforcement, that information may not fully
actualize the situation that took place before the clinician. Data only offers so
much information, and as will be discussed later, DHSS already has access to
data relating to practitioners who dispense opioids. As a law enforcement order
that prevents physicians from access to the data, this progrm will not work to
fight the crisis it was put in place to solve.
The Executive Order is ambiguous and vague on what would trigger an
investigation into prescribing and dispensing practices. PDMPs in other states
(and St. Louis County) do not include reports for opioids that are prescribed to
patients suffering from cancer or receiving end-of-life treatment. 108 Counties
that feature older residents suffering from chronic pain may trigger higher
reporting rates than a county with younger residents. Certain physicians’
practice areas may lend themselves to higher opioid prescribing rates than those
practicing in other areas, such as pain management, surgery, and rehabilitation,
as opposed to those practicing in pediatrics, dermatology, and pathology. 109 The
Executive Order is not clear what actions will be taken if dispenser data is not
reported.
IV. DUPLICATION AND EXECUTIVE ORDER
While the Executive Order that Governor Greitens signed in July of 2017
was finally operational in November of 2017, the order as written remains
problematic. If we take this order as written, the focus of the order is to punish
physicians without a focus on utilizing the goals of public health to combat the
opioid crisis. The information the PDMP seeks is available to law enforcement
via other methods. This PDMP is not the most efficient means to combat the
crisis and create a streamlined patient-care system.
The BNDD in the DHSS for Missouri requires all practitioners maintain
strict record keeping regarding controlled substances. The guidelines they have
for prescribers include specific criteria that must be met when dispensing
controlled substances, including: (1) “[t]he prescriber must be properly
registered;” (2) “[t]he patient must desire treatment for a legitimate illness or
condition;” (3) “[a] practitioner must establish a legitimate need through
assessment, utilizing pertinent technical diagnostic modalities [and] [t]here must
be a legitimate practitioner/patient relationship;” and (4) “[t]here must be
reasonable correlations between the drugs prescribed and the patient’s legitimate

107. Mo. Exec. Order No. 17-18 (July 17, 2017).
108. St. Louis County Prescription Drug Monitoring Program, supra note 89.
109. Benjamin Levy, et al., Trends in Opioid Analgesic–Prescribing Rates by Specialty, U.S.,
2007–2012, 49 AM. J. PREVENTATIVE MED. 409 (2015).
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needs.” 110 Before the practitioner writes a prescription, the controlled substances
have been “tracked from the day they are made until they are dispensed to a
patient.” 111 When a physician determines there is need for prescription opioids,
they must keep a log of “all controlled substances received, administered,
dispensed, or otherwise disposed of” as well as a separate record of controlled
substances documented in the patient’s chart, including the strength, quantities,
and refills. 112 Those “charts are open for inspection and copying” by BNDD and
must be made available within three days if requested. 113 Practitioners are to
have the ability to review the record of controlled substances to determine which
patients are receiving which drugs and how often. 114
Pharmacists in Missouri are also guided by strict rules when filling
prescriptions for controlled substances. Any time a controlled substance moves
from one person to another, there must be documentation demonstrating the
changing of hands, and all records regarding controlled substances must be kept
for at least two years per state and federal law. 115 These records must be “readily
retrievable” and turned over to BNDD for “inspection and copying” as
necessary. 116 A pharmacy is required to take inventory of controlled substances
received into the facility and to keep a receipt of the drugs stocked, as well as
maintain a record of all controlled substances that are filled. 117 Information that
is required when dispensing opioids includes: date of dispense, patient name,
patient address, drug name, strength, dosage form, and quantity. 118 Employees
of pharmacies are also warned to be aware of “professional patients:” those who
“patronize 3 or more pharmacies routinely.” 119
While prescribers and pharmacists have to keep stringent records regarding
the dispensing of controlled substances (including opioids), the BNDD has also
historically worked with DHSS to ensure controlled substances are being
properly handled and dispensed. The DHSS “works with law enforcement and
other agencies to minimize the abuse of controlled substances in the state.” 120
Of the activities in which BNDD participates, one mirrors the previously
110. BUREAU OF NARCOTICS & DANGEROUS DRUGS, MO. DEP’T OF HEALTH & SENIOR
SERVS., CONTROLLED SUBSTANCE GUIDELINES FOR MISSOURI PRACTITIONERS 16–17 (Jan. 1,
2016).
111. Id. at 6.
112. Id. at 9–10.
113. Id. at 10.
114. Id. at 9.
115. BUREAU OF NARCOTICS & DANGEROUS DRUGS, MO. DEP’T OF HEALTH & SENIOR
SERVS., CONTROLLED SUBSTANCE GUIDELINES FOR MISSOURI PHARMACIES 6 (May 11, 2016).
116. Id.
117. Id. at 6–7.
118. Id. at 7.
119. Id.
120. Request for Prescribing and Dispensing Information, MO. DEP’T HEALTH & SENIOR
SERVS., http://health.mo.gov/safety/bndd/ (last visited Oct. 13, 2018).
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mentioned behavior that practitioners and pharmacists must undertake: DHSS
must “maintain[] a registry, as required by state law, of the individuals and firms
who prescribe, dispense or otherwise conduct activities which involve controlled
substances.” 121 Other activities include: conducting inspections of records held
by those who dispense opioids; following up on complaints filed about potential
mishandling of controlled substances; completing audits of those who handle
opioids; and working “to correct or prevent unlawful practices, when detected,
through education, or … administrative action against the registration of the
firms or individuals involved.” 122 Working with the primary goal of law
enforcement, the information that BNDD requests is to be de-identified of
individual patient information. When requesting information to investigate
whether controlled substances are being misused, the specific information that
they seek includes the prescriber, pharmacy, drug name, strength and quantity,
and date the drug was dispensed. 123
The majority of Missouri also participates in a statewide HIE. Missouri
Health Connection (MHC) is a system for participants across the state of
Missouri to share EMRs. Currently, MHC has approximately 1,930 health
systems and hospitals participating across the state. 124 The sharing of EMRs
allows a physician treating a patient visiting St. Louis to view the patient’s
medical history and records from the patient’s primary care provider in
Springfield. The sharing of this information can be vital, especially in
determining which, if any, prescriptions the physician should write. While the
purpose of the MHC is to create a system for efficient information sharing and
better patient outcomes, the information from this system is shared among
providers. 125
While by law practitioners and pharmacists must keep records of controlled
substances that are prescribed and dispensed, MHC’s President Angie Bass
believes that for law enforcement to be involved effectively, “data in the right
place is key.” 126 MHC has implemented tools in order to help streamline the
process of checking patient information; when a patient with an EMR in the
system has a recent prescription for opioids, the current treating physician will
be alerted within the system. 127 The purpose of these alerts is to achieve “better

121. Id.
122. Id.
123. Id.
124. Current HIE Participants, MO. HEALTH CONNECTION, https://missourihealthconnection.
org/current-hie-participants/ (last visited Oct. 13, 2018).
125. See Patients, MO. HEALTH CONNECTION, https://missourihealthconnection.org/patients/
(last visited Oct. 13, 2018).
126. Telephone Interview with Angie Bass, President & Chief Exec. Officer, Mo. Health
Connection (Nov. 15, 2017).
127. Id.
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care coordination and clinical decision support.” 128 Alerts within the system
would be generated by prescription history and are meant to help the current
physician from prescribing a duplicate prescription or a prescription that might
react negatively with a different prescription of record. MHC plans to add more
tools in 2018 to help those with access to EMRs become even more efficient in
treating patients and identifying potential drug seekers. 129 The MHC HIE is
similar to a PDMP because providers can see the prescription history of the
patient, but this information is not turned over to law enforcement without a
subpoena or as required by law. Even though this is not a traditional PDMP, it
has the capability of operating like one if MHC has mandatory statewide
participation; if implemented in this way, the HIE would not be a law
enforcement-centered PDMP like the one established by Executive Order in
Missouri.
Clearly, there are already guidelines in place for physicians and pharmacists
to follow regarding the prescription and dispensing of controlled substances,
including opioids. These guidelines are meant to track potentially dangerous
drugs that have high chances of misuse and addiction. The BNDD, under the
Missouri DHSS, also works with these entities to ensure that each and every pill
is accounted for, as well as investigate and audit diversions, or losses, of
controlled substances. 130 The DHSS maintains their own records of those who
handle or dispense controlled substances but also can request information
regarding a controlled substance from both prescribers and pharmacists if there
is an irregularity or sign of potential abuse, either through theft, loss, or
overprescribing. MHC works to ensure that all EMRs contain necessary and vital
information to help physicians to make the appropriate choice when prescribing.
With all this information currently available, what value will Missouri’s new
PDMP add? While the Executive Order may attempt to streamline data on opioid
prescriptions, that information is already available. Contracting with a pharmacy
benefit management organization to analyze the data and then requiring
dispensers to submit that data to DHSS to determine if there is a need for
investigation is repetitive of the role that BNDD (working within DHSS) already
plays in investigations and audits of facilities with controlled substances. While
Phase Three of the Executive Order, to purchase technology to monitor data,
could help the entire state, MHC, operating across the state, allows physicians
to monitor health information for a patient in front of them. While this is a local,
specific form of monitoring, it is keeping the judgment in the hands of the
medical professionals as opposed to law enforcement.

128. MHC Alerts, MO. HEALTH CONNECTION (August 2017), https://missourihealthconnec
tion.org/wp-content/uploads/2017/09/MHC-Alerts-Flyer-August-2017.pdf.
129. Telephone Interview with Angie Bass, supra note 126.
130. Request for Prescribing and Dispensing Information, supra note 120.
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Nebraska as a Model for Missouri

For Missouri to have the opportunity to truly be successful in minimizing
opioid-related deaths and cutting down on overprescribing and abusers, the state
legislature should look to the state of Nebraska and its PDMP as a possible
model. Nebraska, which was the first state to mandate use of its PDMP, has
created a partnership that combines its HIE with the PDMP, allowing the two to
exist together. 131 Nebraskans believe that this combination allows the state “to
close the loop with all prescriptions.” 132 Called the NeHII, the purpose is to “aid
providers in making treatment decisions with a more robust medical history of
their patient thus aiding and improving the quality and safety of patient care.” 133
The system utilizes a program called DrFirst Medication History that allows
prescribers, for “purposes of preventing adverse drug events and prescription
drug monitoring,” to submit a request to “serve up queried medication history to
the requestor.” 134 DrFirst then takes the prescription data generated during the
visit and submits that information to the PDMP, which will allow pharmacists
and other dispensers to access that information at the time of treatment. 135
The transmission of electronic data allows the pharmacists to have access
not only to current prescriptions waiting to be filled, but also to the prescription
history, which may help identify patients who are abusing the system and
seeking opioids with the purpose of abusing them. 136 This system enables health
care providers to “monitor the care and treatment” of the patients they are
treating and confirm that the prescriptions “are used for medically appropriate
purposes.” 137 Proponents recognize that this system has the potential to help curb
the state’s opioid-related problems in a real and meaningful way by allowing
physicians and pharmacists to have access to the information. 138
The program not only allows access to patient information in the course of
treatment, but also alerts practitioners when “patients access several dispensed
opioid prescriptions and indicate instances in which overlapping prescriptions
131. What is the Prescription Drug Monitoring Program?, NEB. DEP’T OF HEALTH & HUMAN
SERVS. (2017), http://dhhs.ne.gov/publichealth/PDMP/Documents/PDMP%20General%20Infor
mation_v4.pdf.
132. Joseph Goedert, Nebraska to Use State HIE to Track All Filled Prescriptions, HEALTH
DATA MGMT. (July 13, 2017), https://www.healthdatamanagement.com/news/nebraska-to-usestate-hie-to-track-all-filled-prescriptions.
133. What is the Prescription Drug Monitoring Program?, supra note 131.
134. Nebraska Prescription Drug Monitoring Program (PDMP), NEB. DEP’T OF HEALTH &
HUMAN SERVS., https://www.npharm.org/Files/Newsandevents/AnnualConvention/2016Conven
tion/NeHII-PDMP.pdf.
135. Goedert, supra note 132.
136. Kate Monica, Nebraska HIE Implements Improved Prescription Monitoring,
EHRINTELLIGENCE (July 12, 2017), https://ehrintelligence.com/news/nebraska-hie-implementsimproved-prescription-monitoring.
137. What is the Prescription Drug Monitoring Program?, supra note 131.
138. Monica, supra note 136.
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of opioid medication are being dispensed to the same patient.” 139 When
identifying some of these markers that indicate abuse, physicians and
pharmacists can work to intervene with the patient by reducing the dose amount
or substituting a different treatment plan. 140 In this way, it is clear that the focus
of the combined HIE and PDMP is to address the public health concerns related
to opioid abuse, not merely punish abusers and prescribers. While this new
program was seen as an added layer in an already complicated industry, there
was little resistance to the program, and now Nebraska is experiencing a “100
percent compliance rate for prescription reporting.” 141 By combining the PDMP
with the HIE, Nebraska has created a public health-centered program working
to identify and address issues prior to administering opioids.
If Missouri still feels, either from political pressure or public relations, that
they need its PDMP to combat the use of opioids in the state, then Missouri
should adopt a model similar to Nebraska’s by integrating the PDMP into the
HIE system already in place. PDMPs can be an effective tool in identifying and
addressing those who are abusing opioids. For the PDMP to be most effective,
it must be centered on addressing the public health issue of opioid addiction as
opposed to focusing on punishment. Nebraska has incorporated its PDMP with
a focus on public health with its EMR system. By doing so, they have closed the
gap of duplicate information, allowing physicians and pharmacists to see
prescription history of a patient to determine not only if they are merely an
opioid seeker, but also offer efficient or alternative treatment. If this model is
adopted by Missouri, this could allow physicians to deliver patient-centered care
and to make the best decisions about a patient’s course of treatment in the
moment based on the information found on the HIE. Both pharmacists and
physicians would still be required to track the number of controlled substances
that are dispensed and remain subject to inspection by the BNDD allowing for a
continued check by law enforcement on opioids.
V. CONCLUSION
The United States has been struggling to address the growing number of
opioid-related deaths and overdoses for the past two decades. Every state has
responded by implementing a PDMP in order to track opioid prescriptions, with
Missouri joining the other forty-nine in 2017. These programs tend to be
designed with one of two goals: public health and law enforcement. In order to
most effectively end the cycle of addiction to opioids, these programs need a
public health-centered approach to not only prevent abusers from obtaining
multiple prescriptions for opioids, but to also offer intervention strategies to help
those who are addicted.
139. Id.
140. See id.
141. Goedert, supra note 132.
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St. Louis County, Missouri attempted to address the issues occurring in the
community by starting a county-operated PDMP. Once this program began in
2017, many other counties across the state joined the PDMP to have access to
their resources. Governor Eric Greitens also decided the state needed to do more
and signed the Executive Order directing the DHSS to implement a statewide
PDMP. This program, as written, aims to punish prescribers and abusers. More
importantly, the law already requires all prescribers and dispensers of controlled
substances to record the information that the PDMP seeks, and that data is
available to the BNDD upon request. The BNDD also already has the power,
from the DHSS, to investigate and audit those who deal with controlled
substances.
This PDMP will likely prove to be an additional drain on resources (the
contract with the pharmacy benefit organization and the purchase of technology
to monitor the data), requiring additional funds to monitor information that is
already being recorded. If Missouri chooses to continue with their statewide
PDMP, the program should be integrated with the HIE that Missouri already has
in place. Like Nebraska, this would allow physicians to get access to prescription
history (something not currently allowed under Missouri’s PDMP) and treat
patients while consulting their EMR to look for any problematic drug
combinations or overprescribing of opioids. In this way, Missouri will be taking
a more holistic approach to combatting opioid-related deaths and overdoses
while continuing to provide efficient, patient-centered care.
COLLEEN A. KINSEY *

* Juris Doctor, Saint Louis University School of Law (anticipated 2019); Master of Arts in
Teaching, Missouri State University; Bachelor of Arts, Missouri State University. I would like to
thank Professor Sandra Johnson for her guidance and encouragement during the writing process
and the Editorial Board of Volume 12. Additionally, I would like to thank my family for their
unwavering support.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

260

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

[Vol. 12:239

